At the end of last month, Brazilian authorities announced that they would import 6 million doses of “CoronaVac”, a vaccine against Wuhan pneumonia (new coronavirus disease, COVID-19) made by China’s Sinovac Biotech, for joint development and clinical trials.
Two days later, Brazil’s National Health Supervisory Agency (ANVISA) made a U-turn, issuing a statement to contradict the president’s statement, pointing out that it would approve the import of 6 million doses of the vaccine “CoronaVac”, which was under development by China’s research partner, and would be jointly developed with Instituto Butantan in São Paulo, and would undergo phase III clinical trials.
Earlier, however, Reuters reported that Brazil’s National Health Surveillance Agency (ANVISA) announced on 9 October that “serious adverse reactions” to the CoronaVac vaccine had been reported on 29 October and that clinical trials had been urgently suspended; however, the Agency did not say whether the incident had occurred in other countries where trials were also under way, nor did it say why the October announcement had not been made until today.
Recent Comments